---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127117"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:34:06.519351+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# uniQure AMT-130 shows dose-dependent clinical benefit in Huntington's; NfL below baseline at 30 months

## Summary
- AMT-130 showed favorable cUHDRS difference of 0.39 (low-dose at 30 months) and 1.24 (high-dose at 18 months) vs natural history.
- Mean CSF NfL low-dose cohort 6.6% below baseline at 30 months; high-dose cohort near baseline at 18 months.
- AMT-130 generally well-tolerated; 4 AMT-130-related SAEs (CNS inflammation) in high-dose cohort managed with steroids.
- Company plans regulatory interactions in Q1 2024 and next clinical update mid-2024.

## SEC filing metadata
- accession: 0001104659-23-127117
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923127117/0001104659-23-127117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923127117/tm2333072d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127117
- JSON: https://secwatch.observer/filing/0001104659-23-127117.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.